$NTLA
Intellia Therapeutics, Inc.

2016 Q2 Form 10-Q Financial Statement

#000119312516612779 Filed on June 03, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q4
Revenue $4.210M $1.780M $1.690M
YoY Change 205.07% 37.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.730M $3.250M $2.810M
YoY Change 31.8% 192.79% 83.66%
% of Gross Profit
Research & Development $7.423M $5.225M $4.375M
YoY Change 277.57% 281.11% 375.54%
% of Gross Profit
Depreciation & Amortization $240.0K $187.0K $130.0K
YoY Change 242.86% 466.67%
% of Gross Profit
Operating Expenses $7.423M $5.225M $4.375M
YoY Change 277.57% 281.11% 78.57%
Operating Profit -$6.946M -$6.694M -$5.491M
YoY Change 102.98% 460.17%
Interest Expense $50.00K $10.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.900M -$6.689M -$5.491M
YoY Change 101.64% 459.75% 124.12%
Income Tax $0.00 $0.00 -$246.0K
% Of Pretax Income
Net Earnings -$6.900M -$6.689M -$5.245M
YoY Change 126.97% 511.99% 114.08%
Net Earnings / Revenue -163.9% -375.79% -310.36%
Basic Earnings Per Share
Diluted Earnings Per Share -$360.9K -$190.6K -$149.6K
COMMON SHARES
Basic Shares Outstanding 36.00M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $300.7M $64.20M $75.80M
YoY Change 1418.69% 673.47%
Cash & Equivalents $300.7M $64.19M $75.82M
Short-Term Investments
Other Short-Term Assets $1.200M $700.0K $800.0K
YoY Change 140.0% 166.67%
Inventory
Prepaid Expenses
Receivables $1.000M $1.000M $1.000M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $302.9M $65.94M $77.63M
YoY Change 1258.31% 668.57%
LONG-TERM ASSETS
Property, Plant & Equipment $4.421M $4.228M $2.708M
YoY Change 194.73% 802.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.299M $5.375M $1.805M
YoY Change 724.75% 501.67%
Total Long-Term Assets $7.720M $9.603M $4.513M
YoY Change 306.32% 652.17%
TOTAL ASSETS
Total Short-Term Assets $302.9M $65.94M $77.63M
Total Long-Term Assets $7.720M $9.603M $4.513M
Total Assets $310.6M $75.54M $82.14M
YoY Change 1183.57% 667.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.042M $1.206M $1.360M
YoY Change -30.53% 580.0%
Accrued Expenses $4.288M $2.973M $2.788M
YoY Change 38.32% 26.73%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $21.62M $10.96M $10.70M
YoY Change 100.16% 345.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $363.0K $349.0K $323.0K
YoY Change -93.95% -59.63%
Total Long-Term Liabilities $363.0K $349.0K $323.0K
YoY Change -93.95% -59.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.62M $10.96M $10.70M
Total Long-Term Liabilities $363.0K $349.0K $323.0K
Total Liabilities $21.98M $11.31M $11.02M
YoY Change 30.83% 255.42%
SHAREHOLDERS EQUITY
Retained Earnings -$35.53M -$28.63M -$21.94M
YoY Change
Common Stock $259.1M $1.483M $735.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $223.6M -$27.14M -$21.20M
YoY Change
Total Liabilities & Shareholders Equity $310.6M $75.54M $82.14M
YoY Change 1183.57% 667.65%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q4
OPERATING ACTIVITIES
Net Income -$6.900M -$6.689M -$5.245M
YoY Change 126.97% 511.99% 114.08%
Depreciation, Depletion And Amortization $240.0K $187.0K $130.0K
YoY Change 242.86% 466.67%
Cash From Operating Activities $67.55M -$9.420M -$5.490M
YoY Change 2998.62% -295.44% 249.68%
INVESTING ACTIVITIES
Capital Expenditures -$1.150M $1.008M -$840.0K
YoY Change 98.28% 95.35% 200.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$1.150M -$1.010M -$840.0K
YoY Change -2.54% 94.23% 82.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 170.1M -1.200M -450.0K
YoY Change 56600.0% -127.71% -111.31%
NET CHANGE
Cash From Operating Activities 67.55M -9.420M -5.490M
Cash From Investing Activities -1.150M -1.010M -840.0K
Cash From Financing Activities 170.1M -1.200M -450.0K
Net Change In Cash 236.5M -11.63M -6.780M
YoY Change 18092.31% -234.76% -447.69%
FREE CASH FLOW
Cash From Operating Activities $67.55M -$9.420M -$5.490M
Capital Expenditures -$1.150M $1.008M -$840.0K
Free Cash Flow $68.70M -$10.43M -$4.650M
YoY Change 2389.13% -342.29% 260.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35996265 shares
CY2015Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
900000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18479000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2617932 shares
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.69
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2558755 shares
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
0 shares
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2558755 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4464000
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1483000
CY2016Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
400000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
28832000
CY2016Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
625000
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
-27142000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
4878000
CY2016Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
349000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
370000
CY2016Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1948000
CY2016Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
88620000
CY2016Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6781000
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1206000
CY2016Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2973000
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28625000
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75540000
CY2016Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2753000
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
0
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4736000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
9786000
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
10960000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4598000
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
11800000
CY2016Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5375000
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
3300000
CY2016Q1 us-gaap Assets
Assets
75540000
CY2016Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
30005000
CY2016Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1000000
CY2016Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4228000
CY2016Q1 us-gaap Assets Current
AssetsCurrent
65937000
CY2016Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
30005000
CY2016Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
745000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64192000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
212000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9845000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
456374 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.04
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2558755 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2558755 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
735000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
600000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1281000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-21201000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
323000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
907000
CY2015Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
88557000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6547000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1360000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2788000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21936000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82139000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3765000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10695000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1805000
CY2015Q4 us-gaap Assets
Assets
82139000
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
30000000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1000000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2708000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
77626000
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
30000000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
810000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75816000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
4822000
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23175000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
516000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-1093000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
68000
CY2015Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1286000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1195000
CY2015Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
300000
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1195000
CY2015Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
307000
CY2015Q1 us-gaap Income Tax Effects Allocated Directly To Equity
IncomeTaxEffectsAllocatedDirectlyToEquity
1000000
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-102000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
115000
CY2015Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
68000
CY2015Q1 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-102000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
6070000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8634000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-516000
CY2015Q1 us-gaap Costs And Expenses
CostsAndExpenses
2481000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4328000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1371000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-561000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
360000
CY2015Q1 us-gaap Depreciation
Depreciation
33000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1110000
CY2015Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
4644000
CY2015Q1 ntla Payments Of Temporary Equity Issuance Costs
PaymentsOfTemporaryEquityIssuanceCosts
16000
CY2015Q1 ntla Earnings Per Common Unit Basic And Diluted
EarningsPerCommonUnitBasicAndDiluted
-0.85
CY2015Q1 ntla Weighted Average Number Of Common Units Outstanding Basic And Diluted
WeightedAverageNumberOfCommonUnitsOutstandingBasicAndDiluted
1284000 shares
CY2015Q1 ntla In Process Research And Development Acquired But Not Yet Paid
InProcessResearchAndDevelopmentAcquiredButNotYetPaid
1400000
CY2015Q1 ntla Collaboration Consideration Allocated To Equity
CollaborationConsiderationAllocatedToEquity
2600000
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9421000
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.013 pure
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.89
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4392000 shares
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001652130
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y10M24D
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.877 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.83
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
INTELLIA THERAPEUTICS, INC.
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2161558 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.98
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2016Q1 dei Trading Symbol
TradingSymbol
NTLA
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
676000 shares
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1008000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-6689000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-65000
CY2016Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1777000
CY2016Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
895000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6694000
CY2016Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2823000
CY2016Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
200000
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6689000
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
CY2016Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
918000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
812000
CY2016Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
26000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-778000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-11624000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1008000
CY2016Q1 us-gaap Costs And Expenses
CostsAndExpenses
8471000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1195000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5225000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-134000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3246000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-87000
CY2016Q1 us-gaap Depreciation
Depreciation
187000
CY2016Q1 ntla Initial Public Offering Costs Incurred But Not Yet Paid
InitialPublicOfferingCostsIncurredButNotYetPaid
454000
CY2016Q1 ntla Payments Of Temporary Equity Issuance Costs
PaymentsOfTemporaryEquityIssuanceCosts
100000
CY2016Q1 ntla In Process Research And Development Acquired But Not Yet Paid
InProcessResearchAndDevelopmentAcquiredButNotYetPaid
400000

Files In Submission

Name View Source Status
0001193125-16-612779-index-headers.html Edgar Link pending
0001193125-16-612779-index.html Edgar Link pending
0001193125-16-612779.txt Edgar Link pending
0001193125-16-612779-xbrl.zip Edgar Link pending
d160065d10q.htm Edgar Link pending
d160065dex311.htm Edgar Link pending
d160065dex312.htm Edgar Link pending
d160065dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g160065txpg017.jpg Edgar Link pending
ntla-20160331.xml Edgar Link completed
ntla-20160331.xsd Edgar Link pending
ntla-20160331_cal.xml Edgar Link unprocessable
ntla-20160331_def.xml Edgar Link unprocessable
ntla-20160331_lab.xml Edgar Link unprocessable
ntla-20160331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending